argenex (NASDAQ:ARGX) Price Target Raised to $1,185.00

argenex (NASDAQ:ARGX) had its price objective upped by Guggenheim from $1,135.00 to $1,185.00 in a research report released on Friday morning,Benzinga reports. Guggenheim currently has a buy rating on the stock.

A number of other equities analysts have also recently weighed in on the company. Wells Fargo & Company lifted their price target on argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a research note on Monday, June 1st. Weiss Ratings raised shares of argenex from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday, July 6th. Royal Bank Of Canada raised their target price on shares of argenex from $890.00 to $945.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Citigroup raised their target price on shares of argenex from $1,152.00 to $1,182.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Finally, HC Wainwright reissued a “buy” rating and issued a $940.00 target price on shares of argenex in a research report on Thursday, June 25th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, argenex currently has a consensus rating of “Moderate Buy” and an average target price of $1,050.50.

argenex Price Performance

Shares of NASDAQ ARGX opened at $918.22 on Friday. The stock has a market capitalization of $57.44 billion, a price-to-earnings ratio of 35.26, a PEG ratio of 1.21 and a beta of 0.45. The stock’s fifty day simple moving average is $868.28 and its 200 day simple moving average is $815.22. argenex has a 52-week low of $587.37 and a 52-week high of $953.58.

argenex (NASDAQ:ARGX) last announced its earnings results on Tuesday, July 21st. The company reported $7.32 EPS for the quarter, beating the consensus estimate of $5.86 by $1.46. argenex had a return on equity of 43.59% and a net margin of 32.19%.The business had revenue of $1.54 billion during the quarter, compared to the consensus estimate of $1.45 billion. As a group, analysts anticipate that argenex will post 26.95 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ARGX. Assenagon Asset Management S.A. purchased a new position in argenex during the fourth quarter valued at approximately $20,475,000. Sivik Global Healthcare LLC purchased a new stake in argenex in the 4th quarter worth approximately $1,261,000. Mirae Asset Global Investments Co. Ltd. lifted its position in argenex by 22.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,846 shares of the company’s stock worth $9,121,000 after buying an additional 2,018 shares in the last quarter. M&T Bank Corp lifted its position in argenex by 34.8% in the 4th quarter. M&T Bank Corp now owns 4,980 shares of the company’s stock worth $4,188,000 after buying an additional 1,286 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its stake in shares of argenex by 65.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,226 shares of the company’s stock valued at $2,713,000 after buying an additional 1,280 shares during the period. 60.32% of the stock is owned by institutional investors and hedge funds.

More argenex News

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenex reported Q2 EPS of $7.32, topping estimates, on revenue of $1.54 billion versus expectations of $1.45 billion, highlighting strong operating momentum and profitability. Q2 earnings report and conference call
• Positive Sentiment: Reuters reported that global sales of Vyvgart jumped in the second quarter, a key driver for argenex’s growth and a major reason the stock has been gaining investor attention. Reuters article on Vyvgart sales
• Positive Sentiment: Oppenheimer, RBC, and Guggenheim all raised price targets and maintained bullish ratings, signaling increased Street confidence in argenex’s growth trajectory and pipeline prospects.
• Positive Sentiment: A Seeking Alpha note highlighted surging profitability, robust cash generation, and operational leverage, while pointing to pipeline catalysts such as empasiprubart as additional upside potential. Seeking Alpha rating upgrade article
• Neutral Sentiment: Short-interest data showed 0 shares reported, which provides little actionable signal for investors because the figures appear unchanged and unusually low.
• Negative Sentiment: Citizens JMP trimmed its price target slightly from $944 to $932, though it still kept a positive rating, making this more of a minor caution than a bearish call.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.